Salud financiera de hoja de balance de Immunovant
Salud financiera controles de criterios 6/6
Immunovant tiene un patrimonio de los accionistas total de $449.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $515.7M y $66.7M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$472.94m |
| Patrimonio | US$449.05m |
| Total pasivo | US$66.65m |
| Activos totales | US$515.71m |
Actualizaciones recientes sobre salud financiera
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Oct 16
We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Jul 18We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08Recent updates
Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Oct 16Immunovant: Switching Lead Candidates Increases Risk
Oct 14We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Jul 18Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive
Jun 27We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Apr 19Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)
Apr 04Immunovant: An Intriguing And Developing Story
Jan 25Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Jan 12We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Sep 28Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Jun 14Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans
Mar 08We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Nov 06Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset
Oct 17Immunovant stock down on raising $75M though equity capital
Oct 04We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate
Aug 06Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation
Apr 06We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely
Jun 20Immunovant EPS beats by $0.04
Jun 01argenx rise even as Immunovant pauses the trial for anti-FcRn therapy
Feb 03Immunovant slips 7% on voluntary hold of IMVT-1401 dosing
Feb 02Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management
Jan 14Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?
Dec 30Immunovant (IMVT) Investor Presentation - Slideshow
Nov 16Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($507.4M) de IMVT superan a sus pasivos a corto plazo ($66.7M).
Pasivo a largo plazo: IMVT no tiene pasivos a largo plazo.
Historial y análisis de deuda-patrimonio
Nivel de deuda: IMVT está libre de deudas.
Reducción de la deuda: IMVT actualmente no tiene deuda, sin embargo, no podemos comparar con hace 5 años ya que no disponemos de datos de ese periodo.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: IMVT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: IMVT dispone de suficiente cash runway para 1.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 34.1% cada año.